Search

Displaying results 2191 - 2200 of 10000 in total
  1. Drug

    Deucravacitinib

    go.drugbank.com/drugs/DB16650
    ApprovedInvestigational

    [A246938, A246943] This selectivity towards TYK2 may lead to an improved safety profile of deucravacitinib, as nonselective JAK inhibitors are associated with a range of adverse effects such as altered … Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor.

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  2. Drug

    Enalaprilat

    go.drugbank.com/drugs/DB09477
    ApprovedInvestigational

    Enalaprilat is poorly orally available and is therefore only available as an intravenous injection for the treatment of hypertension when oral therapy is not possible. … Used in the treatment of hypertension, enalapril is an ACE inhibitor that prevents Angiotensin Converting Enzyme (ACE) from transforming angiotensin I into angiotensin II.

    Products: Vasotec IV
  3. Drug

    Bimekizumab

    go.drugbank.com/drugs/DB12917
    ApprovedInvestigational

    [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment … Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis.

  4. Drug

    Tiopronin

    go.drugbank.com/drugs/DB06823
    Approved

    As cystinuria is a relatively rare disease, tiopronin is classified as an orphan drug and is not patented in the United States. … Tiopronin is used as a second-line therapy to control the rate of cystine precipitation and excretion, and prevent kidney stone formation.

  5. Drug

    Tonapofylline

    go.drugbank.com/drugs/DB12569
    Investigational

    Tonapofylline has been used in trials studying the treatment of Heart Failure, Renal Insufficiency, and Congestive Heart Failure.

    Categories: Receptor, Adenosine A1
  6. Drug

    Sulconazole

    go.drugbank.com/drugs/DB06820
    Approved

    Sulconazole, brand name Exelderm, is a broad-spectrum anti-fungal agent available as a topical cream and solution. … Sulconazole nitrate, the active ingredient, is an imidazole derivative that inhibits the growth of common pathogenic dermatophytes, making it an effective treatment for tinea cruris and tinea corporis

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  7. Drug

    Pyrimethamine

    go.drugbank.com/drugs/DB00205
    ApprovedInvestigationalVet approved

    One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.

    Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 Enzyme InhibitorsSynonyms: 2,4-Diamino-5-(P-chlorophenyl)-6-ethylpyrimidine
  8. Drug

    Disulfiram

    go.drugbank.com/drugs/DB00822
    ApprovedInvestigational

    A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  9. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. … [A253717, L43652] Because CTLA-4 is an immune checkpoint that plays a vital role in regulating T cell-mediated immune response, tremelimumab is considered an immune checkpoint inhibitor, which is an emerging

  10. Drug

    Racemethionine

    go.drugbank.com/drugs/DB13972
    Approved

    A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.

    Mixtures: Extra Once A Day, A/o-26 - Caplet